February 7, 2017
Gilead’s income driven down by lower sales of hepatitis C virus products
Gilead Sciences has reported net income for the fourth quarter 2016 of $3.1 billion, which is $1.6 billion less compared to same period last year.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Chronic Hepatitis C
March 15, 2016
FDA Approves ZEPATIER for the Treatment of Chronic Hepatitis C Infection
On January 28, 2016, the United States Food and Drug Administration (FDA) approved Zepatier (elbasvir and grazoprevir) for the treatment of chronic genotype 1 or 4 hepatitis C virus (HCV) infection in adults.